Assess whether to resubmit, meet, or pause the program (bec638)

SITUATION A payer demanding RWE the protocol cannot generate put phase-3 protocol with endpoint-sensitivity issues in front of regulatory-affairs lead in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / CMC and Development Pathways close is to resubmit, meet, or from phase-3 protocol with endpoint-sensitivity issues, and the live options are To resubmit, meet,, Pause the program.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; phase-3 protocol with endpoint-sensitivity issues already has the discriminator after a payer demanding RWE the protocol cannot generate. 2. Keep Pause the program in force until phase-3 protocol with endpoint-sensitivity issues is completed after a payer demanding RWE the protocol cannot generate for regulatory-affairs lead. 3. Treat phase-3 protocol with endpoint-sensitivity issues as To resubmit, meet, because both readings appear after a payer demanding RWE the protocol cannot generate. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision to resubmit, meet, or turns on in phase-3 protocol with endpoint-sensitivity issues.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a payer demanding RWE the protocol cannot generate and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after a payer demanding RWE the protocol cannot generate). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for regulatory-affairs lead - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in phase-3 protocol with endpoint-sensitivity issues that a second reviewer can re-perform